Here's a sentence we've been waiting a long time to write: there is now a generic version of a twice-a-year HIV prevention shot. On November 2, 2026, the U.S. Food and Drug Administration gave tentative approval to Dr. Reddy's Laboratories for a generic form of injectable lenacapavir, the long-acting PrEP sold in the U.S. under the brand name Yeztugo. Global health groups say the generic will cost about $40 per person per year in 120 low- and middle-income countries.
That's huge news for the world. But if you live in the U.S., the story is more complicated, and it's worth understanding, especially as World AIDS Day approaches on December 1. The same weeks that brought a scientific win also brought cuts to the community groups that help people actually get tested and get on PrEP.
We believe HIV prevention is sexual health, and sexual health is a right. So let's break down what happened, what it means for you, and how to protect yourself and your people.
What Happened
PrEP (pre-exposure prophylaxis) is medicine that HIV-negative people take to prevent HIV. For years, that mostly meant a daily pill. Lenacapavir changed the game: two injections a year, with clinical trials showing about 96% effectiveness. Gilead's brand-name version was approved for prevention in June 2025.
The new generic approval is "tentative," which is the FDA's standard designation for a generic while the original drug is still under patent. In plain terms: it clears the way for the U.S. government and global partners to buy the generic for use abroad, but it doesn't put a cheap version on U.S. pharmacy shelves. According to Unitaid, first supplies are expected to reach countries by the end of 2026, with wider availability in 2027. More than 125,000 people in 10 African countries have already started lenacapavir through earlier programs.
For comparison, Science has reported the U.S. brand-name price at roughly $28,000 a year. No U.S. launch date or price for a generic has been announced.
What It Means for You in the U.S.
The good news: if you have insurance, PrEP is likely already free or close to it. In June 2025, the Supreme Court ruled 6-3 in Kennedy v. Braidwood to keep the Affordable Care Act rule that most private plans must cover recommended preventive care, including PrEP, with no cost-sharing. That covers the medicine plus related visits and lab tests. An analysis presented at IDWeek 2026 found that 91% of PrEP claims had zero cost-sharing after federal guidance was clarified in late 2024.
The same research found that the long-acting shot is reaching many people who are new to PrEP; among women who got it, about half had never used PrEP before. That matters, because daily pills don't fit every life, every schedule or every living situation.
The caution: KFF notes that the Court's decision rests on the HHS Secretary's power over the panel that makes these recommendations, and that power could be used to change or delay them in the future. In other words, coverage is protected for now, not forever.
If you're shopping for a plan for 2027, our guide to ACA open enrollment and staying covered walks through the basics.
Who's Most Affected
HIV in the U.S. has never been evenly shared. KFF's analysis of federal data shows Black people make up about 12% of the population but about 40% of people living with HIV, and Latino people make up about 19% of the population but 26% of people living with HIV. Gay and bisexual men accounted for the majority of new diagnoses in 2022, diagnoses among Latino gay and bisexual men rose between 2018 and 2022, and transgender women are disproportionately affected. The South accounts for more than half of new diagnoses. The CDC estimates about 64% of the more than 1.2 million people who could benefit from PrEP aren't getting it.
Those numbers aren't about anyone's worth or behavior. They reflect who has been shut out of health care, stable housing, affirming providers and honest sex ed for generations. Data on trans men, nonbinary people, Indigenous communities and disabled people is often thin or missing entirely, which is its own kind of gap.
The Funding Fight Behind the Headlines
In July 2026, Roll Call reported that the White House budget office told the CDC it would not renew a five-year grant that directly funded 96 community-based HIV prevention organizations. KFF found those groups operated in 31 states, Washington, D.C., Puerto Rico and the U.S. Virgin Islands, with nearly half the money going to the South, and that many focused on reaching Black, Latino and transgender people. They provided HIV and STI testing, linkage to care, and PrEP navigation.
The CDC shifted some money to state and local health departments instead, but its September supplemental funding came in at $91 million, about 24% less than expected, and five eligible health departments received nothing. Health departments are encouraged, but not required, to pass funds on to community groups. Roll Call reported that the administration did not offer an explanation when asked; advocates argue the move contradicts the federal goal of ending the HIV epidemic by 2030.
Looking ahead, the White House's FY2027 budget request would eliminate core CDC HIV prevention funding while keeping the Ending the HIV Epidemic initiative. Congress decides the final numbers, and for FY2026 it largely rejected similar proposals. We believe community-based organizations, often run by and for the people most affected, are the backbone of HIV prevention, and that cutting them makes the medical breakthroughs harder to reach.
What You Can Do
- Know your status. Find free or low-cost testing near you with the HIV.gov testing locator, or ask about at-home self-tests, which can give results in about 20 minutes.
- Ask about PrEP. Use the CDC's PrEP provider locator to find a clinic, including ones that serve uninsured patients or offer PrEP navigation. You can ask whether pills or the shot fit your life better.
- Get help paying. If you're uninsured or underinsured, check NASTAD's list of state PrEP assistance programs, which can cover medicine, labs and visits.
- Use your coverage. If your insurer tries to charge you for PrEP, ask why. Under the ACA, most private plans must cover it without cost-sharing.
- Contact your members of Congress. Find your representative at house.gov and your senators at senate.gov, then tell them where you stand on HIV prevention funding and direct support for community organizations. A short, personal message counts.
- Support local HIV organizations. Volunteer, donate if you can, share their testing events, and show up for World AIDS Day gatherings in your area.
- Talk about it. Stigma keeps people from testing. Talking about PrEP and HIV as ordinary health care, with partners, friends and family, is a real act of care.
The Takeaway
A twice-yearly HIV prevention shot with a $40 generic for much of the world is a genuine milestone, and the people who fought for global access deserve credit. In the U.S., PrEP is still covered for most insured people, but the community programs that connect people to it are under strain. Science can give us the tools; it takes all of us to make sure everyone can reach them.
Empower Pleasure doesn't endorse candidates. Updated as of November 11, 2026. Facts can change quickly, so check the linked sources for the latest.
Sources
- Unitaid (2026). U.S. FDA approves first generic injectable lenacapavir for HIV prevention
- LGBTQ Nation (2026). FDA approves generic version of twice-yearly PrEP injection that could substantially lower the price
- Contagion Live (2026). Real-World Data Show Lenacapavir PrEP Reaching New Users
- KFF (2025). Kennedy v. Braidwood: The Supreme Court Upheld ACA Preventive Services but That's Not the End of the Story
- KFF. The HIV/AIDS Epidemic in the United States: The Basics
- KFF (2026). The Future of CDC HIV Prevention Funding for Community Organizations
- Roll Call (2026). Trump administration puts kibosh on HIV prevention funding
- KFF (2026). Domestic HIV Funding in the White House FY2027 Budget Request
- UNAIDS (2026). 2026 World AIDS Day
Photo: cottonbro studio / Pexels
